Перспективы применения пробиотических препаратов при острых инфекциях респираторного тракта

Острые  вирусные  инфекции верхних  дыхательных  путей  (ВДП)  являются  одним  из самых  распространенных заболеваний в мире. Заболевание возникает  у лиц всех возрастных  групп и в некоторых случаях может иметь неблагоприятные осложнения и исходы. Одна из приоритетных задач практического здравоохранения состоит в возможности профилактики и лечения  острой респираторной вирусной инфекции и ее осложнений. В представленном обзоре рассмотрены собственные механизмы  неспецифической защиты человеческого организма  от вирусной инфекции. Обобщены  результаты исследований по изучению роли симбионтной кишечной микрофлоры в профилактике острой инфекции ВДП. На основании имеющихся литературных  данных представлены  основные  аспекты биологических свойств пробиотических бактерий,  которые,  как правило,  рассматриваются в контексте  их модулирующего  влияния на воспалительную иммунную реакцию.  Проведен  анализ имеющихся данных о снижении риска возникновения, продолжительности и выраженности симптомов  респираторной инфекции при приеме пробиотических препаратов  (ПБП) как в детском возрасте,  так и во взрослой популяции. Обсуждается  вопрос  штаммоспецифического эффекта  ПБП.  В статье рассмотрены основные  возможные  молекулярные противовирусные механизмы  ПБП, за счет которых симбионтные бактерии усиливают противовирусный ответ.

1. Allander T., Tammi M.T., Eriksson M. et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl. Acad. Sci. USA. 2005; 102 (36): 12891-12896. https://doi.org/10.1073/pnas.0504666102.

2. Rossi G.A., Colin A.A. Infantile respiratory syncytial virus and human rhinovirus infections: respective role in inception and persistence of wheezing. Eur. Respir. J. 2015; 45 (3): 774-789. https://doi.org/10.1183/09031936.00062714.

3. Openshaw P.J., Tregoning J.S. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin. Microbiol. Rev. 2005; 18 (3): 541-555. https://doi.org/10.1128/CMR.18.3.541-555.2005.

4. Gauguet S., D'Ortona S., Ahnger-Pier K. et al. Intestinal microbiota of mice inf luences resistance to Staphylococcus aureus pneumonia. Infect. Immun. 2015; 83 (10): 4003-4014. https://doi.org/10.1128/IAI.00037-15.

5. Ichiohe T., Pang I.K., Kumamoto Y. et al. Microbiota regulates immune defense against respiratory tract inf luenza A virus infection. Proc. Natl. Acad. Sci. USA. 2011; 108 (13): 5354-5359. https://doi.org/10.1073/pnas.1019378108.

6. Salva S., Alvarez S. The role of microbiota and immunobiotics in granulopoiesis of immunocompromised hosts. Front. Immunol. 2017; 8: 507. https://doi.org/10.3389/fimmu.2017.00507.

7. Lopez P., Gonzalez-Rodrıguez I., Gueimonde M. et al. Immune response to Bifidobacterium bifidum strains support Treg/Th17 plasticity. PLoS ONE. 2011; 6 (9): e24776. https://doi.org/10.1371/journal.pone.0024776.

8. Izumo T., Maekawa T., Ida M. et al. Effect of intranasal administration of Lactobacillus pentosus S-PT84 on inf luenza virus infection in mice. Int. Immunopharmacol. 2010; 10 (9): 1101-1106. https://doi.org/10.1016/j.intimp.2010.06.012.

9. Kobayashi N., Saito T., Uematsu T. et al. Oral administration of heat-killed Lactobacillus pentosus strain b240 augments protection against inf luenza virus infection in mice. Int. Immunopharmacol. 2011; 11 (2): 199-203. https://doi.org/10.1016/j.intimp.2010.11.019.

10. Hori T., Kiyoshima J., Shida K., Yasui H. Effect of intranasal administration of Lactobacillus casei Shirota on inf luenza virus infection of upper respiratory tract in mice. Clin. Diagn. Lab. Immunol. 2001; 8 (3): 593-597. https://doi.org/10.1128/CDLI.8.3.593-597.2001.

11. Yasui H., Kiyoshima J., Hori T. Reduction of inf luenza virus titer and protection against inf luenza virus infection in infant mice fed Lactobacillus casei Shirota. Clin. Diagn. Lab. Immunol. 2004; 11 (4): 675-679. https://doi.org/10.1128/CDLI.11.4.675-679.2004.

12. Pang I.K., Iwasaki A. Control of antiviral immunity by pattern recognition and the microbiome. Immunol. Rev. 2012; 245 (1): 209-226. https://doi.org/10.1111/j.1600-065X.2011.01073.x.

13. Villena J., Suzuki R., Fujie H. et al. Immunobiotic Lactobacillus jensenii modulates the Toll-like receptor 4-induced inf lammatory response via negative regulation in porcine antigen-presenting cells. Clin. Vaccine Immunol. 2012; 19 (7): 1038-1053. https://doi.org/10.1128/CVI.00199-12.

14. Nagai T., Makino S., Ikegami S. et al. Effects of oral administration of yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 and its exopolysaccharides against inf luenza virus infection in mice. Int. Immunopharmacol. 2011; 11 (12): 2246-2250. https://doi.org/10.1016/j.intimp.2011.09.012.

15. Kawase M., He F., Kubota A. et al. Oral administration of lactobacilli from human intestinal tract protects mice against inf luenza virus infection. Lett. Appl. Microbiol. 2010; 51 (1): 6-10. https://doi.org/10.1111/j.1472-765X.2010.02849.x.

16. Harata G., He F., Hiruta N. et al. Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 inf luenza virus infection by regulating respiratory immune responses. Lett. Appl. Microbiol. 2010; 50 (6): 597-602. https://doi.org/10.1111/j.1472-765X.2010.02844.x.

17. Kawase M., He F., Kubota A. et al. Heat-killed Lactobacillus gasseri TMC0356 protects mice against inf luenza virus infection by stimulating gut and respiratory immune responses. FEMS Immunol. Med. Microbiol. 2012; 64 (2): 280-288. https://doi.org/10.1111/j.1574-695X.2011.00903.x.

18. Maruo T., Gotoh Y., Nishimura H. et al. Oral administration of milk fermented with Lactococcus lactis subsp. cremoris FC protects mice against inf luenza virus infection. Lett. Appl. Microbiol. 2012; 55 (2): 135-140. https://doi.org/10.1111/j.1472-765X.2012.03270.x.

19. Goto H., Sagitani A., Ashida N. et al. Anti-inf luenza virus effects of both live and non-live Lactobacillus acidophilus L-92 accompanied by the activation of innate immunity. Br. J. Nutr. 2013; 110 (10): 1810-1818. https://doi.org/10.1017/S0007114513001104.

20. Yasui H., Kiyoshima J., Hori T., Shida K. Protection against inf luenza virus infection of mice fed Bif idobacterium breve YIT4064. Clin. Diagn. Lab. Immunol. 1999; 6 (2): 186-192.

21. Gabryszewski S.J., Bachar O., Dyer K.D. et al. Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection. J. Immunol. 2011; 186 (2): 1151-1161. https://doi.org/10.4049/jimmunol.1001751.

22. Tomosada Y., Chiba E., Zelaya H. et al. Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection. BMC Immunol. 2013; 14: 40. https://doi.org/10.1186/1471-2172-14-40.

23. Gill H.S., Rutherfurd K.J., Cross M.L., Gopal P.K. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am. J. Clin. Nutr. 2001; 74 (6): 833-839. https://doi.org/10.1093/ajcn/74.6.833.

24. Di Cerbo A., Palmieri B., Aponte M. et al. Mechanisms and therapeutic effectiveness of lactobacilli. J. Clin. Pathol. 2016; 69 (3): 187-203. https://doi.org/10.1136/jclinpath-2015-202976.

25. Hatakka K., Savilahti E., Pönkä A. et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. Br. Med. J. 2001; 322 (7298): 1327. https://doi.org/10.1136/bmj.322.7298.1327.

26. Hojsak I., Snovak N., Abdovic S. et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin. Nutr. 2010; 29 (3): 312-316. https://doi.org/10.1016/j.clnu.2009.09.008.

27. Kumpu M., Kekkonen R.A., Kautiainen H. et al. Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial. Eur. J. Clin. Nutr. 2012; 66 (9): 1020-1023. https://doi.org/10.1038/ejcn.2012.62.

28. Luoto R., Ruuskanen O., Waris M. et al. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2014; 133 (2): 405-413. https://doi.org/10.1016/j.jaci.2013.08.020.

29. Kukkonen K., Savilahti E., Haahtela T. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics. 2008; 122 (1): 8-12. https://doi.org/10.1542/peds.2007-1192.

30. Rautava S., Salminen S., Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy - a randomised, double-blind, placebo-controlled study. Br. J. Nutr. 2009; 101 (11): 1722-1726. https://doi.org/10.1017/S0007114508116282.

31. Agustina R., Kok F.J., van de Rest O. et al. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics. 2012; 129 (5): e1155-1164. https://doi.org/10.1542/peds.2011-1379.

32. Turchet P., Laurenzano M., Auboiron S., Antoine J.M. Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in freeliving elderly subjects: a randomised, controlled pilot study. J. Nutr. Health Aging. 2003; 7 (2): 75-77.

33. Guillemard E., Tondu F., Lacoin F., Schrezenmeir J. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br. J. Nutr. 2010; 103 (1): 58-68. https://doi.org/10.1017/S0007114509991395.

34. Cobo Sanz J.M., Mateos J.A., Muñoz Conejo A. [Effect of Lactobacillus casei on the incidence of infectious conditions in children]. Nutr. Hosp. 2006; 21 (4): 547-551 (in Spanish).

35. Lin J.S., Chiu Y.H., Lin N.T. et al. Different effects of probiotic species/strains on infections in preschool children: a double-blind, randomized, controlled study. Vaccine. 2009; 27 (7): 1073-1079. https://doi.org/10.1016/j.vaccine.2008.11.114.

36. Nocerino R., Paparo L., Terrin G. et al. Cow's milk and rice fermented with Lactobacillus paracasei CBA L74 prevent infectious diseases in children: a randomized controlled trial. Clin Nutr. 2017; 36 (1): 118-125. https://doi.org/10.1016/j.clnu.2015.12.004.

37. Maldonado J., Cañabate F., Sempere L. et al. Human milk probiotic Lactobacillus fermentum CECT57I6 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J. Pediatr. Gastroenterol. Nutr. 2012; 54 (1): 55-61. https://doi.org/10.1097/MPG.0b013e3182333f18.

38. Hojsak I., Močić Pavić A., Kos T. et al. Bifidobacterium animalis subsp. lactis in prevention of common infections in healthy children attending day care centers - randomized, double blind, placebo-controlled study. Clin. Nutr. 2016; 35 (3): 587-591. https://doi.org/10.1016/j.clnu.2015.05.004.

39. Garaiova I., Muchová J., Nagyová Z. et al. Probiotics and vitamin C for the prevention of respiratory tract infections in children attending preschool: a randomised controlled pilot study. Eur. J. Clin. Nutr. 2015; 69 (3): 373-379. https://doi.org/10.1038/ejcn.2014.174.

40. de Vrese M., Winkler P., Rautenberg P. et al. Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. Clin. Nutr. 2005; 24 (4): 481-491. https://doi.org/10.1016/j.clnu.2005.02.006.

41. Guillemard E., Tondu F., Lacoin F., Schrezenmeir J. Consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial. Br. J. Nutr. 2010; 103 (1): 58-68. https://doi.org/10.1017/S0007114509991395.

42. Makino S., Ikegami S., Kume A. et al. Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1. Br. J. Nutr. 2010; 104 (7): 998-1006. https://doi.org/10.1017/S000711451000173X.

43. Namba K., Hatano M., Yaeshima T. et al. Effects of Bifidobacterium longum BB536 administration on inf luenza infection, inf luenza vaccine antibody titer, and cell-mediated immunity in the elderly. Biosci. Biotechnol. Biochem. 2010; 74 (5): 939-945. https://doi.org/10.1271/bbb.90749.

44. Hamilton-Miller J.M. Probiotics and prebiotics in the elderly. Postgrad. Med. J. 2004; 80 (946): 447-451. https://doi.org/10.1136/pgmj.2003.015339.

45. Davidson L.E., Fiorino A.M., Snydman D.R., Hibberd P.L. Lactobacillus GG as an immune adjuvant for live-attenuated inf luenza vaccine in healthy adults: a randomized doubleblind placebo-controlled trial. Eur. J. Clin. Nutr. 2011; 65 (4): 501-507. https://doi.org/10.1038/ejcn.2010.289.

46. Akatsu H., Arakawa K., Yamamoto T. et al. Lactobacilli in jelly enhances the effect of inf luenza vaccination in Elderly Individuals. J. Am. Geriatr. Soc. 2013; 61 (10): 1828-1830. https://doi.org/10.1111/jgs.12474.

47. Rizzardini G., Eskesen D., Calder P.C. et al. Evaluation of the immune benef its of two probiotic strains Bif idobacterium animalis ssp. lactis, BB-12 and Lactobacillus paracasei ssp. paracasei, L. casei 431 in an inf luenza vaccination model: a randomized, double-blind, placebo controlled study. Brit. J. Nutr. 2012; 107 (6): 876-884. https://doi.org/10.1017/S000711451100420X.

48. Hao Q., Dong B.R., Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database System. Rev. 2015; (2): CD006895. https://doi.org/10.1002/14651858.CD006895.pub3.

49. Wang Y., Li X., Ge Т. et al. Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016; 95 (31): e4509. https://doi.org/10.1097/MD.0000000000004509.

50. Fitzgerald K.A. NLR-containing inf lammasomes: Central mediators of host defense and inf lammation. Eur. J. Immunol. 2010; 40 (3): 595-598. https://doi.org/10.1002/eji.201040331.

51. Coulombe F., Fiola S., Akira S. et al. Muramyl dipeptide induces NOD2-dependent Ly6Chigh monocyte recruitment to the lungs and protects against inf luenza virus infection. PLoS One. 2012; 7 (5): e36734. https://doi.org/10.1371/journal.pone.0036734.

52. Lehtoranta L., Pitkäranta A., Korpela R. Probiotics in respiratory virus infections. Eur. J. Clin. Microbiol. Infect. Dis. 2014; 33 (8): 1289-1302. https://doi.org/10.1007/s10096-014-2086-y.

53. Kim T.H., Lee H.K. Differential roles of lung dendritic cell subsets against respiratory virus infection. Immune Netw. 2014; 14 (3): 128-137. https://doi.org/10.4110/in.2014.14.3.128.

54. Manzanares W., Lemieux M., Langlois P.L., Wischmeyer P.L. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit. Care. 2016; 20: 262. https://doi.org/10.1186/s13054-016-1434-y.